You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BTK inhibitor

Showing 1 - 25 of 7,607
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

CLL/SLL Trial (lisaftoclax +BTK inhibitor, BTK inhibitor)

Not yet recruiting
  • CLL/SLL
  • lisaftoclax +BTK inhibitor
  • BTK inhibitor
  • (no location specified)
Oct 26, 2023

B-cell Non Hodgkin Lymphoma Trial in Xuzhou (regimen with BTK inhibitor +Anti-CD19 CAR T cells)

Recruiting
  • B-cell Non Hodgkin Lymphoma
  • regimen with BTK inhibitor +Anti-CD19 CAR T cells
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023

Mantle Cell Lymphoma, Mantle Cell Lymphoma Refractory Trial (Glofitamab, Pirtobrutinib, Obinutuzumab)

Not yet recruiting
  • Mantle Cell Lymphoma
  • Mantle Cell Lymphoma Refractory
  • (no location specified)
Apr 18, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • BTK inhibitor
  • PD-1 inhibitor
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023

Waldenstrom Macroglobulinemia Trial (Zanubrutinib)

Not yet recruiting
  • Waldenstrom Macroglobulinemia
  • (no location specified)
Nov 28, 2022

Primary CNS Lymphoma Trial in Zhengzhou (the dose-escalation phase)

Recruiting
  • Primary Central Nervous System Lymphoma
  • the dose-escalation phase
  • Zhengzhou, Henan, China
    Oncology Department of The First Affiliated Hospital of Zhengzho
May 30, 2022

Neuromyelitis Optica Trial in Beijing (zanubrutinib)

Recruiting
  • Neuromyelitis Optica
  • Beijing, Beijing, China
    XuanWu Hospital
May 15, 2022

Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia Trial in Wuhan (BTK inhibitor+ Fludarabine +

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +4 more
  • BTK inhibitor+ Fludarabine + Cyclophosphamide + CAR-T-CD19 Cells
  • Fludarabine + Cyclophosphamide + CAR-T-CD19 Cells
  • Wuhan, Hubei, China
    Union Hospital, Huazhong University of Science and Technology
Oct 13, 2021

Mantle Cell Lymphoma Trial in Beijing (DTRMWXHS-12)

Active, not recruiting
  • Mantle Cell Lymphoma
  • Beijing, China
    Peking University Cancer Hospital
Aug 18, 2021

Mantle Cell Lymphoma Trial in Houston (Ibrutinib)

Recruiting
  • Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Nov 1, 2022

Hepatic Impairment Trial in Kiel (M2951 (BTK inhibitor))

Completed
  • Hepatic Impairment
  • M2951 (BTK inhibitor)
  • Kiel, Germany
    CRS Clinical Research Services Kiel GmbH
Jul 9, 2021

Waldenström's Macroglobulinemia (WM) Trial in China (Zanubrutinib)

Completed
Has Results
  • Waldenström's Macroglobulinemia (WM)
  • Beijing, Beijing, China
  • +10 more
Mar 7, 2022

CNS B-Cell Non-Hodgkin Lymphoma, Recurrent CNS Lymphoma, Refractory CNS Lymphoma Trial in Houston (Ibrutinib, Nivolumab)

Recruiting
  • Central Nervous System B-Cell Non-Hodgkin Lymphoma
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 13, 2022

Chronic Lymphocytic Leukemia Trial in Houston (Ibrutinib, Venetoclax)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Sep 21, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Duarte (procedure, biological, drug)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Biospecimen Collection
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Jan 30, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Acalabrutinib, Obinutuzumab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 14, 2022

Waldenstrom Macroglobulinemia Trial in China (Ibrutinib)

Active, not recruiting
  • Waldenstrom Macroglobulinemia
  • Changchun, China
  • +5 more
Jan 27, 2023

Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 Trial in Rochester (drug,

Active, not recruiting
  • Metastatic Melanoma
  • +6 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 13, 2023

Activated B-cell DLBCL (ABC DLBCL) Trial in United Kingdom, United States (Acalabrutinib)

Active, not recruiting
Has Results
  • Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
  • Los Angeles, California
  • +6 more
Dec 1, 2022

B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in China (Orelabrutinib, Recombinant humanized mAb MIL62 injection)

Active, not recruiting
  • B-cell Lymphoma Recurrent
  • B-cell Lymphoma Refractory
  • Orelabrutinib
  • Recombinant humanized monoclonal antibody MIL62 injection
  • Bengbu, Anhui, China
  • +9 more
Nov 11, 2022

Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2022

MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,

Active, not recruiting
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +9 more
  • BTK inhibitor PCI-32765
  • +5 more
  • Columbus, Ohio
    Ohio State University Medical Center
Jun 27, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome Trial in Italy, United Kingdom, United States

Active, not recruiting
Has Results
  • Chronic Lymphocytic Leukemia
  • +3 more
  • Boston, Massachusetts
  • +11 more
Nov 23, 2022

Richter Transformation Trial in Austria, Denmark, Germany (Tislelizumab, Zanubrutinib)

Recruiting
  • Richter Transformation
  • Vienna, Austria
  • +11 more
Mar 8, 2022

Waldenstrom Macroglobulinemia Trial in Japan (Ibrutinib, Rituximab)

Active, not recruiting
Has Results
  • Waldenstrom Macroglobulinemia
  • Chiba, Japan
  • +8 more
Jan 27, 2023